of dopamine by pharmacodynamic antagonism. Contraindicated.dopexamineMonitor Closely (1)trifluoperazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)trifluoperazine and dosulepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.doxepinMonitor Closely (1)trifluoperazine and doxepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)doxepin, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. doxepin, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.doxylamineMonitor Closely (1)doxylamine and trifluoperazine both increase sedation. Use Caution/Monitor.dronedaroneSerious - Use Alternative (1)trifluoperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)dronedarone will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.droperidolMonitor Closely (2)droperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. droperidol and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duloxetineMinor (1)duloxetine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.efavirenzMonitor Closely (1)efavirenz and trifluoperazine both decrease QTc interval. Use Caution/Monitor.eletriptanMonitor Closely (1)eletriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eliglustatMonitor Closely (1)eliglustat and trifluoperazine both decrease QTc interval. Use Caution/Monitor.enalaprilMinor (1)trifluoperazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.encorafenibMonitor Closely (1)encorafenib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.entrectinibMonitor Closely (1)entrectinib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.ephedrineMonitor Closely (2)trifluoperazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrineMonitor Closely (3)trifluoperazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. trifluoperazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicMonitor Closely (2)trifluoperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia. trifluoperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine racemic and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.ergoloid mesylatesMonitor Closely (1)ergoloid mesylates, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ergotamineMonitor Closely (1)ergotamine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eribulinMonitor Closely (1)eribulin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.erythromycin baseSerious - Use Alternative (1)trifluoperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (1)trifluoperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (1)trifluoperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (1)trifluoperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.esketamine intranasalMonitor Closely (1)esketamine intranasal, trifluoperazine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.estazolamMonitor Closely (1)estazolam and trifluoperazine both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)trifluoperazine and ethanol both increase sedation. Use Caution/Monitor.Minor (1)ethanol, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.etomidateMonitor Closely (1)etomidate and trifluoperazine both increase sedation. Use Caution/Monitor.eucalyptusMinor (1)trifluoperazine and eucalyptus both increase sedation. Minor/Significance Unknown.fenfluramineMonitor Closely (2)trifluoperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. trifluoperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylMonitor Closely (1)fentanyl, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).Serious - Use Alternative (1)fentanyl, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalSerious - Use Alternative (1)fentanyl intranasal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalSerious - Use Alternative (1)fentanyl transdermal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalSerious - Use Alternative (1)fentanyl transmucosal, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fesoterodineMonitor Closely (3)fesoterodine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. fesoterodine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fexinidazoleMonitor Closely (1)fexinidazole will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.fezolinetantContraindicated (1)trifluoperazine will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsfingolimodMonitor Closely (1)fingolimod and trifluoperazine both decrease QTc interval. Use Caution/Monitor.flavoxateMonitor Closely (3)flavoxate decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainideMonitor Closely (1)trifluoperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.flibanserinMonitor Closely (1)flibanserin, trifluoperazine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fluconazoleSerious - Use Alternative (1)trifluoperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluoxetineMonitor Closely (2)trifluoperazine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely. fluoxetine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fluphenazineMonitor Closely (2)fluphenazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. fluphenazine and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)fluphenazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.flurazepamMonitor Closely (1)flurazepam and trifluoperazine both increase sedation. Use Caution/Monitor.fluvoxamineMonitor Closely (1)fluvoxamine and trifluoperazine both increase QTc interval. Modify Therapy/Monitor Closely.formoterolMonitor Closely (1)trifluoperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.foscarnetMonitor Closely (1)trifluoperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosinoprilMinor (1)trifluoperazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.frovatriptanMonitor Closely (1)frovatriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ganaxoloneMonitor Closely (1)trifluoperazine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)gemifloxacin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.givosiranSerious - Use Alternative (1)givosiran will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling.glycopyrrolateMonitor Closely (1)trifluoperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)trifluoperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.glycopyrrolate inhaledMonitor Closely (3)glycopyrrolate inhaled decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. glycopyrrolate inhaled decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)trifluoperazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetronMonitor Closely (1)granisetron and trifluoperazine both decrease QTc interval. Use Caution/Monitor.guanfacineMonitor Closely (1)guanfacine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.haloperidolMonitor Closely (2)haloperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. haloperidol and trifluoperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)haloperidol will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.henbaneMonitor Closely (3)henbane decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. henbane decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.homatropineMonitor Closely (3)homatropine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. homatropine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hydrocodoneSerious - Use Alternative (1)hydrocodone, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).hydromorphoneMonitor Closely (1)hydromorphone and trifluoperazine both increase sedation. Use Caution/Monitor.hydroxyzineMonitor Closely (2)hydroxyzine and trifluoperazine both increase sedation. Use Caution/Monitor. hydroxyzine and trifluoperazine both